A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway

ReachMD CME

CME credits: 0.50
Claim your CME credit at https://reachmd.com/programs/cme/a-novel-therapeutic-approach-in-myeloid-malignancies-targeting-the-neddylation-pathway/11694/
Please note: This activity is no longer available for continuing education credit. There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.